In a phase 3 trial of first-line treatment for metastatic NSCLC with PD-L1 ≥25%, the combination yielded a median OS of 11.9 months and PFS of 3.9 months, with no significant improvement over chemotherapy (HR for death 0.85, p=0.20). This evidence concerns the gene CD274 and non-small cell lung carcinoma.